Lymphoblastic Lymphoma is an indication for drug development with over 40 pipeline drugs currently active. According to GlobalData, preregistered drugs for Lymphoblastic Lymphoma have a 66.67% likelihood of approval (LoA) indication benchmark. GlobalData’s report assesses how phase transition success rate (PTSR) and likelihood of approval (LoA) scores for pipeline drugs in Lymphoblastic Lymphoma compared to historical benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

Lymphoblastic Lymphoma overview

Lymphoblastic lymphoma (LL) is a rare and aggressive type of non-Hodgkin lymphoma (NHL) that affects immature lymphocytes called lymphoblasts. It can originate from either B-cell or T-cell lymphoblasts, but it is more common in T cells. LL usually involves the lymph nodes in the chest, but it can also affect the bone marrow, the brain and spinal cord, and other organs. LL is most often seen in young adults, especially males. The treatment of LL depends on the subtype, the stage, and the risk factors of the disease. It may include chemotherapy, immunotherapy, radiation therapy, or stem cell transplant. The prognosis of LL varies depending on the response to treatment and other factors.

For a complete picture of PTSR and LoA scores for drugs in Lymphoblastic Lymphoma, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article. 

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.